Safety and Efficacy Study of CD22 CAR-T Cells for Relapsed or Refractory Acute Lymphoblastic Leukemia
Latest Information Update: 06 Dec 2022
At a glance
- Drugs Anti CD22 chimeric antigen receptor T cell therapy-Hebei Senlang Biotechnology (Primary)
- Indications Precursor cell lymphoblastic leukaemia-lymphoma
- Focus Adverse reactions; Therapeutic Use
- Sponsors Hebei Senlang Biotechnology
Most Recent Events
- 18 Sep 2020 New trial record